PODD— AI Stock Forecast & Price Targets
Published 7/10/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live PODD price forecast →
PODD is a high-quality diabetes device franchise (71% gross margins, 23% ROE, 32% TTM sales growth) that has been cut nearly in half YTD to ~$161, creating a genuine quality-on-sale setup — but the stock sits well below its broken SMA200 (~$240, -35% overhead), carries fresh FDA Class I recall liability, and faces a binary Aug 5 earnings print in ~26 days. Recommendation is ACCUMULATE with medium conviction: valuation is more reasonable at 19.6x forward, analyst target ($235) implies material upside, but technicals remain broken and the earnings gap risk argues against sizing aggressively pre-print.
1-4 week view: Do NOT chase into the Aug 5 earnings print (~26 days out). Any starter position should be sized to survive a -15% to -20% gap-down scenario. Preferred entry zone is $150-$158 (near current levels with a stop below $138 52-week low). Reject the model's aggressive $188 near-term forecast — the weekly model has been beaten by naive baseline and daily accuracy at multi-day horizons drifts to >45% MAPE. Trim/take profits into any pre-earnings run into $175-$180 resistance. Earnings is the invalidation event: a soft print or recall charge that breaks $138 flips the setup to avoid.
1-6 month view: Base case is a range-bound recovery to $180-$190 as the recall liability gets quantified and Omnipod 5 international ramp continues. Bull case requires reclaiming the SMA200 (~$220-$240) which would confirm a trend change and align with sell-side consensus ($235). Expected return range: -15% to +35% skewed positive on 12-18 month view but with wide dispersion. What changes my mind: (a) recall scope expands materially or triggers second FDA action, (b) Q2 revenue growth decelerates below +20% Y/Y, (c) gross margin compresses below 68% suggesting warranty/remediation drag is structural.
1-3 year view: Terminal thesis is that PODD is the leading pump platform in a still-underpenetrated Type 1 diabetes market with a credible path into insulin-intensive Type 2, supported by 71% gross margins, a data platform (Omnipod Discover) offering optionality, and international expansion (Spain, broader EU). Consensus 26.75% next-5Y EPS growth against a 19.6x forward multiple is attractive if durable. Biggest structural risks: (1) competitive displacement from Tandem, Medtronic, and potential Abbott/DXCM integrated platforms; (2) reimbursement pressure as pump penetration scales; (3) any recurrence of quality/regulatory issues that damage the brand permanence of Omnipod. If these are managed, the stock can plausibly re-rate back toward $250-$300 over 2-3 years.
Operating quality is unambiguously strong. Q1'26 revenue of $761.7M was up materially year-over-year (TTM sales growth 31.9%), gross margin held at 69.5% (TTM 71.6%), and operating margin was 16.0% with net margin 12.0%. TTM revenue is $2.90B with EBITDA of $602M and $619M operating cash flow against $253M free cash flow — capex has stepped up (Q4'25 capex of $149M is well above the ~$25-30M/qtr run-rate), which is worth watching but consistent with capacity investment behind Omnipod 5. Balance sheet is solid: $480M cash vs $948M debt, current ratio 2.49, debt/equity 0.73, and ROE of 23%/ROIC 13.6% — best-in-class for a med-tech growth name. Valuation is bifurcated: trailing P/E of 36.8 looks expensive, but forward P/E of 19.6 and PEG of 0.73 against 26.8% forward EPS growth are reasonable, and EV/EBITDA of 18.3 is well off peak. The unquantified FDA Class I recall liability is the main asterisk on otherwise pristine fundamentals; the Aug 5 print will be the first real read on any warranty/remediation drag.
The trend is broken across every timeframe visible. On the weekly chart, price collapsed from ~$350 highs to the $138-$160 zone — a >55% drawdown that has re-based the stock but has not yet produced a durable reversal. Daily action shows a base forming in the $140-$165 range with the stock bouncing off the $138.79 52-week low and now sitting at ~$161, still 35% below the SMA200. The intraday 1h chart shows the model projecting a sharp rally to ~$188 (+16%) into early August, but this forecast conflicts with the more reliable daily context and, notably, the weekly forecast which shows the model beaten by a naive baseline (50% vs 83%) — meaning the aggressive near-term upside band should be heavily discounted. RSI at 53 is neutral, price is +3.8% vs SMA20 and +2.7% vs SMA50 (nascent short-term momentum), but the -35% gap to SMA200 defines the ceiling. Key levels: support at $138-$140 (52-week low, must hold), secondary support ~$150; resistance at ~$180 (recent pivot), then the ~$220-$240 zone where the SMA200 and the analyst target ($235) cluster. Until $180 is reclaimed with volume, this remains a base-building setup, not a trend change.
News flow is mixed but net negative on sentiment. The Class I FDA recall and related class-action lawsuit headlines continue to overhang the story, with commentary noting the stock still trades at a premium despite the -47% one-year drawdown. Sell-side has been cutting price targets — Stifel to $225 from $250, Evercore to $180 from $200 — though the consensus target of $235 still implies ~47% upside from spot. Offsetting the negatives: commercial launch of Omnipod 5 and the Omnipod Discover data platform in Spain expands the international footprint, and analyst recommendation of 1.43 (near strong-buy) shows the sell-side is broadly still constructive despite the trims. The signal-versus-noise read: recall liability and the Aug 5 earnings print are the two hard catalysts; everything else (Spain launch, incremental target trims) is second-order. Insider signal is weakly bearish (a senator's spouse sold two lots in the $100-250k range in late April/early May), but this is dated. Retail sentiment is skewed bullish (100% of tagged messages), which in a broken trend is a mild contrarian yellow flag.
- Omnipod 5 commercial launch in Spain (announced this week) — adds another EU market with Omnipod Discover data platform bundled
- Type 2 insulin-intensive label expansion opportunity materially expands TAM beyond Type 1
- Omnipod Discover data platform creates recurring/software monetization layer beyond hardware
- Q1'26 sales growth of 33.9% Q/Q and 31.9% TTM shows category leadership is intact
- 26.75% consensus 5Y EPS growth against 19.6x forward P/E gives a PEG of 0.73
- Unquantified FDA Class I recall liability — warranty/remediation/litigation exposure not yet reflected in numbers
- Aug 5 earnings is a binary event ~26 days away; IV crush and gap risk both directions
- Stock trades -35% below its SMA200 (~$240) — broken weekly trend has not confirmed reversal
- Trailing P/E of 36.8 leaves no cushion if forward growth decelerates
- Analyst target cuts continue (Stifel to $225, Evercore to $180) — sell-side momentum still negative
- Class action lawsuits add legal cost overhang on top of recall
- Competitive threat from Tandem, Medtronic, and potential Abbott/DXCM integrated CGM+pump platforms
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord